Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2025-12-25 @ 1:26 AM
NCT ID:
NCT05872893
Eligibility Criteria:
Inclusion Criteria:
* Patients aged from 1 day to 18 years who are diagnosed with cancer and are eligible for chemotherapy.
* Voluntarily agree to participate by giving written parental permission and child assent.
* Patients with sufficient cardiac function, as determined by the investigator.
Exclusion Criteria:
* Patients with a history of severe hypersensitivity reactions or anaphylaxis related to the use of 5-HT3 receptor antagonists.
* Patients receiving concurrent chemo-radiation therapy.
* Patients diagnosed with cardiac arrhythmias and congenital long QT interval syndrome.
* Known clinically significant drug interactions between chemotherapeutic agents and 5-HT3 receptor antagonists and/or Dexamethasone (e.g. more than 0.8 mg/ml concentrations of 5-fluorouracil may cause precipitation of ondansetron).
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
18 Years
Study:
NCT05872893
Study Brief:
Protocol Section:
NCT05872893